1-20 of 25
Tito Fojo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation

Michael L. Maitland, Julia Wilkerson, Sanja Karovic, Binsheng Zhao, Jessica Flynn, Mengxi Zhou, Patrick Hilden, Firas S. Ahmed, Laurent Dercle, Chaya S. Moskowitz, Ying Tang, Dana E. Connors, Stacey J. Adam, Gary Kelloff, Mithat Gonen, Tito Fojo, Lawrence H. Schwartz, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6464–6474.
https://doi.org/10.1158/1078-0432.CCR-20-1493
Published: 15 December 2020
View article titled, Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation
Open the PDF for Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation in another window
Includes: Supplementary data
Journal Articles

Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters

Eden C. Payabyab, Sanjeeve Balasubramaniam, Maureen Edgerly, Margarita Velarde, Maria J. Merino, Aradhana M. Venkatesan, Harshraj Leuva, Thomas Litman, Susan E. Bates, Tito Fojo
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (20): 4989–5000.
https://doi.org/10.1158/1078-0432.CCR-16-1570
Published: 13 October 2016
View article titled, Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters
Open the PDF for Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters in another window
Journal Articles

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses

Miriam E. Mossoba, David C. Halverson, Roger Kurlander, Bazetta Blacklock Schuver, Ashley Carpenter, Brenna Hansen, Seth M. Steinberg, Syed Abbas Ali, Nishant Tageja, Frances T. Hakim, Juan Gea-Banacloche, Claude Sportes, Nancy M. Hardy, Dennis D. Hickstein, Steven Z. Pavletic, Hanh Khuu, Marianna Sabatini, David Stroncek, Bruce L. Levine, Carl H. June, Jacopo Mariotti, Olivier Rixe, Antonio Tito Fojo, Michael R. Bishop, Ronald E. Gress, Daniel H. Fowler
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4312–4320.
https://doi.org/10.1158/1078-0432.CCR-15-0340
Published: 30 September 2015
View article titled, High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses
Open the PDF for High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses in another window
Journal Articles

Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

Laleh Amiri-Kordestani, Victoria Luchenko, Cody J. Peer, Kambiz Ghafourian, James Reynolds, Deb Draper, Robin Frye, Sue Woo, David Venzon, John Wright, Monica Skarulis, William D. Figg, Tito Fojo, Susan E. Bates, Richard L. Piekarz
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (16): 4499–4507.
https://doi.org/10.1158/1078-0432.CCR-13-0095
Published: 13 August 2013
View article titled, Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
Open the PDF for Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers in another window
Includes: Supplementary data
Journal Articles

Tales of How Great Drugs Were Brought Down by a Flawed Rationale—Response

Edina Komlodi-Pasztor, Dan L. Sackett, Tito Fojo
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1304.
https://doi.org/10.1158/1078-0432.CCR-12-2058
Published: 03 March 2013
View article titled, Tales of How Great Drugs Were Brought Down by a Flawed Rationale—Response
Open the PDF for Tales of How Great Drugs Were Brought Down by a Flawed Rationale—Response in another window
Journal Articles

Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth

Wilfred D. Stein, Julia Wilkerson, Sindy T. Kim, Xin Huang, Robert J. Motzer, Antonio Tito Fojo, Susan E. Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2374–2381.
https://doi.org/10.1158/1078-0432.CCR-11-2275
Published: 16 April 2012
View article titled, Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
Open the PDF for Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth in another window
Includes: Supplementary data
Journal Articles

Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale

Edina Komlodi-Pasztor, Dan L. Sackett, Antonio Tito Fojo
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (1): 51–63.
https://doi.org/10.1158/1078-0432.CCR-11-0999
Published: 02 January 2012
View article titled, Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
Open the PDF for Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale in another window
Includes: Supplementary data
Journal Articles

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

Wilfred D. Stein, James L. Gulley, Jeff Schlom, Ravi A. Madan, William Dahut, William D. Figg, Yang-min Ning, Phil M. Arlen, Doug Price, Susan E. Bates, Tito Fojo
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 907–917.
https://doi.org/10.1158/1078-0432.CCR-10-1762
Published: 15 February 2011
View article titled, Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
Open the PDF for Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy in another window
Includes: Supplementary data
Journal Articles

A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

Ronan J. Kelly, Deborah Draper, Clara C. Chen, Robert W. Robey, William D. Figg, Richard L. Piekarz, Xiaohong Chen, Erin R. Gardner, Frank M. Balis, Aradhana M. Venkatesan, Seth M. Steinberg, Tito Fojo, Susan E. Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (3): 569–580.
https://doi.org/10.1158/1078-0432.CCR-10-1725
Published: 01 February 2011
View article titled, A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
Open the PDF for A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer in another window
Includes: Supplementary data
Journal Articles

Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?

Tito Fojo, David R. Parkinson
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 5972–5980.
https://doi.org/10.1158/1078-0432.CCR-10-1277
Published: 16 December 2010
View article titled, Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?
Open the PDF for Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much? in another window
Journal Articles

A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma

Hui Huang, Michael Menefee, Maureen Edgerly, Sen Zhuang, Herb Kotz, Marianne Poruchynsky, Lyn Mickley Huff, Susan Bates, Tito Fojo
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1634–1641.
https://doi.org/10.1158/1078-0432.CCR-09-0379
Published: 28 February 2010
View article titled, A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma
Open the PDF for A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine

Jame Abraham, Maureen Edgerly, Richard Wilson, Clara Chen, Ann Rutt, Susan Bakke, Rob Robey, Andrew Dwyer, Barry Goldspiel, Frank Balis, Olaf Van Tellingen, Susan E. Bates, Tito Fojo
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3574–3582.
https://doi.org/10.1158/1078-0432.CCR-08-0938
Published: 18 May 2009
View article titled, A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine
Open the PDF for A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine in another window
Includes: Supplementary data
Journal Articles

Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone

Sen H. Zhuang, Y. Elizabeth Hung, Laura Hung, Robert W. Robey, Dan L. Sackett, W. Marston Linehan, Susan E. Bates, Tito Fojo, Marianne S. Poruchynsky
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (24): 7480–7486.
https://doi.org/10.1158/1078-0432.CCR-06-2883
Published: 19 December 2007
View article titled, Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone
Open the PDF for Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone in another window
Includes: Supplementary data
Journal Articles

Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?

Olivier Rixe, Tito Fojo
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (24): 7280–7287.
https://doi.org/10.1158/1078-0432.CCR-07-2141
Published: 19 December 2007
View article titled, Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?
Open the PDF for Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? in another window
Journal Articles

Challenges of Evaluating the Cardiac Effects of Anticancer Agents

Susan E. Bates, Douglas R. Rosing, Tito Fojo, Richard L. Piekarz
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 3871–3874.
https://doi.org/10.1158/1078-0432.CCR-06-1017
Published: 03 July 2006
View article titled, Challenges of Evaluating the Cardiac Effects of Anticancer Agents
Open the PDF for Challenges of Evaluating the Cardiac Effects of Anticancer Agents in another window
Journal Articles

Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma

Richard L. Piekarz, A. Robin Frye, John J. Wright, Seth M. Steinberg, David J. Liewehr, Douglas R. Rosing, Vandana Sachdev, Tito Fojo, Susan E. Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (12): 3762–3773.
https://doi.org/10.1158/1078-0432.CCR-05-2095
Published: 15 June 2006
View article titled, Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma
Open the PDF for Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma in another window
Journal Articles

Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176)

Robert W. Robey, Zhirong Zhan, Richard L. Piekarz, Ganesh L. Kayastha, Tito Fojo, Susan E. Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (5): 1547–1555.
https://doi.org/10.1158/1078-0432.CCR-05-1423
Published: 06 March 2006
View article titled, Increased <em>MDR1</em> Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176)
Open the PDF for Increased <em>MDR1</em> Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176) in another window
Journal Articles

Epidermal Growth Factor Receptor Inhibitors: A Moving Target?

Susan E. Bates, Tito Fojo
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (20): 7203–7205.
https://doi.org/10.1158/1078-0432.CCR-05-1845
Published: 20 October 2005
View article titled, Epidermal Growth Factor Receptor Inhibitors: A Moving Target?
Open the PDF for Epidermal Growth Factor Receptor Inhibitors: A Moving Target? in another window
Journal Articles

A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma

Susan E. Bates, Susan Bakke, Min Kang, Robert W. Robey, Suoping Zhai, Paul Thambi, Clara C. Chen, Sheela Patil, Tom Smith, Seth M. Steinberg, Maria Merino, Barry Goldspiel, Beverly Meadows, Wilfred D. Stein, Peter Choyke, Frank Balis, William D. Figg, Tito Fojo
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (14): 4724–4733.
https://doi.org/10.1158/1078-0432.CCR-0829-03
Published: 21 July 2004
View article titled, A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma
Open the PDF for A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma in another window
Journal Articles

The Histone Deacetylase Inhibitor FK228 Preferentially Enhances Adenovirus Transgene Expression in Malignant Cells

Merrill E. Goldsmith, Masaki Kitazono, Patrick Fok, Takashi Aikou, Susan Bates, Tito Fojo
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5394–5401.
Published: 12 November 2003
View article titled, The Histone Deacetylase Inhibitor FK228 Preferentially Enhances Adenovirus Transgene Expression in Malignant Cells
Open the PDF for The Histone Deacetylase Inhibitor FK228 Preferentially Enhances Adenovirus Transgene Expression in Malignant Cells in another window